Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global GENERIC INJECTABLES market in this environment.
In terms of revenue, this research report indicated that the global GENERIC INJECTABLES market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of GENERIC INJECTABLES industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Baxter International Inc aims at producing XX GENERIC INJECTABLES in 2020, with XX % production to take place in global market, Fresenius Kabi accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of GENERIC INJECTABLES Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in GENERIC INJECTABLES Market?
Baxter International Inc
Fresenius Kabi
Sun Pharmaceutical Industries Ltd
Dr. Reddy's
Hikma Pharmaceuticals
AstraZeneca Plc
Pfizer
Novartis
Mylan N.V
Merck & Co.
Teva Pharmaceutical Industries Ltd
...
Major Type of GENERIC INJECTABLES Covered in XYZResearch report:
Monoclonal Antibodies
Cytokines
Insulin
Vaccines
Others
Application Segments Covered in XYZResearch Market
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Prescription Stores
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global GENERIC INJECTABLES Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Monoclonal Antibodies -Product Introduction and Major Manufacturers
1.1.2 Cytokines -Product Introduction and Major Manufacturers
1.1.3 Insulin -Product Introduction and Major Manufacturers
1.1.4 Vaccines -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global GENERIC INJECTABLES Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China GENERIC INJECTABLES Market
3.1.1 Top Companies leading GENERIC INJECTABLES Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU GENERIC INJECTABLES Market
3.2.1 Top Companies leading GENERIC INJECTABLES Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA GENERIC INJECTABLES Market
3.3.1 Top Companies leading GENERIC INJECTABLES Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan GENERIC INJECTABLES Market
3.4.1 Top Companies leading GENERIC INJECTABLES Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India GENERIC INJECTABLES Market
3.5.1 Top Companies leading GENERIC INJECTABLES Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia GENERIC INJECTABLES Market
3.6.1 Top Companies leading GENERIC INJECTABLES Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America GENERIC INJECTABLES Market
3.7.1 Top Companies leading GENERIC INJECTABLES Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America GENERIC INJECTABLES Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 GENERIC INJECTABLES Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on GENERIC INJECTABLES Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global GENERIC INJECTABLES Sales and Growth Rate (2021-2026)
5.2 Global GENERIC INJECTABLES Sales Value and Growth Rate (2021-2026)
6 GENERIC INJECTABLES Competitive Analysis
6.1 Baxter International Inc
6.1.1 Baxter International Inc Company Profiles
6.1.2 Baxter International Inc Product Introduction
6.1.3 Baxter International Inc GENERIC INJECTABLES Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Fresenius Kabi
6.2.1 Fresenius Kabi Company Profiles
6.2.2 Fresenius Kabi Product Introduction
6.2.3 Fresenius Kabi GENERIC INJECTABLES Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Sun Pharmaceutical Industries Ltd
6.3.1 Sun Pharmaceutical Industries Ltd Company Profiles
6.3.2 Sun Pharmaceutical Industries Ltd Product Introduction
6.3.3 Sun Pharmaceutical Industries Ltd GENERIC INJECTABLES Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Dr. Reddy's
6.4.1 Dr. Reddy's Company Profiles
6.4.2 Dr. Reddy's Product Introduction
6.4.3 Dr. Reddy's GENERIC INJECTABLES Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Hikma Pharmaceuticals
6.5.1 Hikma Pharmaceuticals Company Profiles
6.5.2 Hikma Pharmaceuticals Product Introduction
6.5.3 Hikma Pharmaceuticals GENERIC INJECTABLES Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 AstraZeneca Plc
6.6.1 AstraZeneca Plc Company Profiles
6.6.2 AstraZeneca Plc Product Introduction
6.6.3 AstraZeneca Plc GENERIC INJECTABLES Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Pfizer
6.7.1 Pfizer Company Profiles
6.7.2 Pfizer Product Introduction
6.7.3 Pfizer GENERIC INJECTABLES Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Novartis
6.8.1 Novartis Company Profiles
6.8.2 Novartis Product Introduction
6.8.3 Novartis GENERIC INJECTABLES Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Mylan N.V
6.9.1 Mylan N.V Company Profiles
6.9.2 Mylan N.V Product Introduction
6.9.3 Mylan N.V GENERIC INJECTABLES Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Merck & Co.
6.10.1 Merck & Co. Company Profiles
6.10.2 Merck & Co. Product Introduction
6.10.3 Merck & Co. GENERIC INJECTABLES Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Teva Pharmaceutical Industries Ltd
7 Conclusion
Overview of the Global Generic Drug CRO (Contract Research Organisation) Market:
The report discusses everything a marketer requires before investing in the global Generic Drug CRO (Contract Research Organisation) M...
The global Generic Allergy Medicine market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in ...
The global Intravitreal (IVT) Injectables market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market playe...
Overview of the Global Generic Drug API Intermediates Solutions Market:
The report discusses everything a marketer requires before investing in the global Generic Drug API Intermediates Solutions Market during the f...
Overview of the Global Generic API Intermediates CDMO Services Market:
The report discusses everything a marketer requires before investing in the global Generic API Intermediates CDMO Services Market during the for...
Overview of the Global Generic Drug Consistency Evaluation Service Market:
The report discusses everything a marketer requires before investing in the global Generic Drug Consistency Evaluation Service Market during...
Overview of the Global Generic Drug Research and Development Services Market:
The report discusses everything a marketer requires before investing in the global Generic Drug Research and Development Services Market ...
Overview of the Global Generic Drug Intermediates CDMO Services Market:
The report discusses everything a marketer requires before investing in the global Generic Drug Intermediates CDMO Services Market during the f...
Overview of the Global Generic and Biosimilar Pharmaceuticals Market:
The report discusses everything a marketer requires before investing in the global Generic and Biosimilar Pharmaceuticals Market during the forec...
Overview of the Global Generic Oncology Sterile Injectable Market:
The report discusses everything a marketer requires before investing in the global Generic Oncology Sterile Injectable Market during the forecast pe...